CommercialPrior AuthMedium impact
Prior Authorization Added for LOQTORZI™
Blue Cross Blue Shield of Wyoming·WY · Oncology, Hematology·Prior Authorization
We identified it
Jun 19, 2026
Summary
BCBSWY now requires prior authorization for LOQTORZI™ (toripalimab-tpzi), a PD-1 inhibitor used to treat recurrent or metastatic nasopharyngeal carcinoma. Authorization must be obtained before administration to avoid claim denials.
Action Required
Immediately: Billing team must update prior authorization requirements for LOQTORZI™ (toripalimab-tpzi) in billing system. Providers must obtain BCBSWY authorization before administering this PD-1 inhibitor for nasopharyngeal carcinoma patients. Claims will be denied without prior authorization.